Advertisement

SABCS 2020

SABCS 2020: First Immunotherapy Combo Well-Tolerated

In an interim analysis of the first immunotherapy combination phase 1b trial with trastuzumab deruxtecan, safety results showed nivolumab with trastuzumab deruxtecan was well tolerated in patients with HER2-positive or HER2-low...

SABCS 2020: Update from the DESTINY-Breast01 trial

In an updated analysis of the phase 2 DESTINY-Breast01 study, women with HER2-positive metastatic breast cancer taking antibody-drug conjugate trastuzumab deruxtecan continued to demonstrate favorable efficacy data, durable...

SABCS 2020: Updates on Phase 3 PENELOPE-B

The collaborative Phase 3 PENELOPE-B will be presented at SABCS 2020. No unexpected safety signals were observed. Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival (iDFS) in...

Loading

Advertisement

For latest news and updates
Email-id is invalid

Meeting Coverage